Prevalence and age- dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a compre- hensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042 8. S7.4-35. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta- analysis of genotype-phenotype associations in patients with hyper- trophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800 11. S7.4-36. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopa- thy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:783 831. S7.4-37. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gado- linium enhancement in clinical outcomes for hypertrophic cardio- myopathy. JACC Cardiovasc Imaging. 2012;5:370 7. S7.4-38. O Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867 74. S7.4-39. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast- enhanced magnetic resonance imaging in patients with hypertro- phic cardiomyopathy. Circ Heart Fail. 2010;3:51 8. S7.4-40. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratifica- tion and management. J Am Coll Cardiol. 2017;69:761 73. S7.4-41. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127:585 93. S7.4-42. Francia P, Adduci C, Palano F, et al. Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. 